Navigation Links
SenesTech, Inc. Commences Product Registration Process With Australian Government
Date:11/10/2008

FLAGSTAFF, Ariz., Nov. 10 /PRNewswire/ -- SenesTech, Inc. has launched the regulatory process to register both the active ingredient and the first ContraPest(R) product with the government of Australia. In parallel with laboratory research and testing in the rice field rat species, registration of ContraPest(R) bait will open the door for marketing this unique rodent population management product to the agricultural ministries of Southeast Asia. ContraPest(R) will target the rice field rat, a major rodent pest species for rice agriculture in this region, known to eat or damage a significant portion of rice crops each year.

ContraPest(R) works through disruption of the reproductive potential of female rodents by selectively eliminating the female's supply of egg cells. The direct effect will be to drastically reduce the number of rats in the field. This translates to increased rice yield, and since nearly half of the world's population depends on rice for sustenance, a 10 percent increase in rice yield will feed approximately 380 million people per year. A further benefit to this humane approach to pest population control is the reduced potential for disease, since rodents and their carcasses are vectors for many human illnesses, some life-threatening.

The regulatory process for ContraPest(R) has been initiated with the Australian Pesticides and Veterinary Medicines Authority (APVMA), the Australian agency responsible for oversight of all agricultural chemical and related products that are manufactured or used in Australia. This registration process will be guided by direct consultation with regulatory expertise within the Australian government.

"The APVMA largely sets the standards for agricultural product use in Australasia, so gaining registration by the APVMA will mean nearly instantaneous acceptance of the product by governments with rice-based agriculture across the region," says Timothy L. Vail, Ph.D., Vice President of Manufacturing and Regulations for SenesTech, Inc. "Just as FDA approval is critical for pharmaceuticals in the U.S., moving ContraPest(R) through the regulatory process with the APVMA will secure our ability to manufacture the product under Australian governmental oversight using Good Manufacturing Practices. This guarantees a high standard of product quality and consistency, regardless of a particular manufacturer's location."

For additional information contact Everett Hale at ehale@senestech.com or visit http://www.senestech.com. ContraPest(R) is projected to be available for commercial use in the spring of 2010.

ABOUT: (SenesTech, Inc.) SenesTech is a platform technology company located in Flagstaff, Arizona on the Northern Arizona Center for Emerging Technology campus. SenesTech specializes in environmentally neutral fertility control products for companion animals and wildlife population control.


'/>"/>
SOURCE SenesTech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SenesTech, Inc. Initiates Research Field Trials for ContraPest(R) in Indonesia
2. Arizona-Based SenesTech, Inc., Partners With Australia to Stop Starvation Due to Rice Shortages
3. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
4. Lilly Commences Cash Tender Offer for ImClone Systems at $70 Per Share
5. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
6. Phase 1b/2a Program Commences for RVX-208
7. GSI Group Accepts Shares in Tender Offer for Excel Technology and Commences Subsequent Offering Period
8. Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period
9. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
10. GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
11. Arbios Commences Process to Seek European Marketing Approval for SEPET(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... , June 24, 2016  Regular discussions on a ... take place between the two entities said Poloz. ... Ottawa , he pointed to the country,s ... the federal government. ... said, "Both institutions have common economic goals, why not sit ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... ... 2016 , ... Mosio, a leader in clinical research patient ... and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the hurdle ... and strategies for clinical researchers. , “The landscape of how patients receive and ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016 ... Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & Other ... provider visiongain offers comprehensive analysis of the ... this market will generate revenues of $17.98 billion in ... acquired DVTEL Inc, a leader in software and hardware ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
Breaking Biology News(10 mins):